
SensOmics is revolutionizing healthcare with wearables and AI for remote and responsive services. They leverage IoT, Cloud Computing, and Big Data technologies to monitor vital signs through medical wearables, analyzing data such as heart rate, blood pressure, blood oxygen, body temperature, activity, and sleep. This enables early disease screening, intelligent risk assessment, and proactive health alerts, aiming for comprehensive lifecycle healthcare management. Their products include SensWatch BP for 24/7 blood pressure monitoring and SensWatch Research for real-time monitoring of physiological parameters. They also offer a Data Platform. Their business model appears to involve product sales and potentially data plan subscriptions.

SensOmics is revolutionizing healthcare with wearables and AI for remote and responsive services. They leverage IoT, Cloud Computing, and Big Data technologies to monitor vital signs through medical wearables, analyzing data such as heart rate, blood pressure, blood oxygen, body temperature, activity, and sleep. This enables early disease screening, intelligent risk assessment, and proactive health alerts, aiming for comprehensive lifecycle healthcare management. Their products include SensWatch BP for 24/7 blood pressure monitoring and SensWatch Research for real-time monitoring of physiological parameters. They also offer a Data Platform. Their business model appears to involve product sales and potentially data plan subscriptions.
What they do: Medical-grade wearables + AI-driven cloud analytics for continuous monitoring of vital signs (heart rate, blood pressure, blood oxygen, temperature, activity, sleep).
Flagship products: SensWatch Blood Pressure (24/7 BP monitoring), SensWatch Research, and a data platform for real-time physiological monitoring.
Founded / HQ: Founded 2015; headquartered in Burlingame, California.
Funding: Seed stage; investors include Asset Management Ventures (AMV, lead) and iSeed Ventures; total funding reported as 600000 USD.
Primary use cases: Early disease screening, pediatric precision medicine / early pediatric disease detection, risk assessment, and proactive health alerts.
Remote patient monitoring, early disease screening and pediatric precision medicine/early pediatric disease detection.
2015
Biotechnology
Seed round dated 2016-01-08; amount reported as undisclosed in funding summaries.
“Investors include Asset Management Ventures (AMV) and iSeed Ventures; AMV is listed as lead investor for the Seed round.”